SCHEMBL3381256

SCHEMBL3381256

c1ccc(-c2csc3ncnc(NCCc4cccs4)c23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.61
HTT P42858 5/20 0.61
NCOA1 Q15788 1/20 0.61
NCOA3 Q9Y6Q9 1/20 0.61
SMN1; SMN2 Q16637 6/20 0.59
MAPK1 P28482 4/20 0.58
TNF P01375 2/20 0.58
NOD1 Q9Y239 2/20 0.58
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
CCNC P24863 1/20 0.54
CDK8 P49336 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54
TSHR P16473 1/20 0.54
FGFR1 P11362 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
ATM Q13315 1/20 0.52
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369138 0.90 ALDH1A1 (0.61) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL2368861 0.90 ATM (0.62) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL2369324 0.90 FGFR1 (0.55) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL2368858 0.88 MAPK1 (0.67) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL2369595 0.85 MAPK1 (0.63) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL3169227 0.82 MAPK1 (0.65) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL2369266 0.81 MAPK1 (0.79) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL1902694 0.81 ESR1 (0.61) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL2368203 0.80 ALDH1A1 (0.69) LMNAHTTNCOA1NCOA3SMN1; SMN2
SCHEMBL1899788 0.80 ALDH1A1 (0.72) LMNAHTTNCOA1NCOA3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885HTT 543/4885NCOA1 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.